Vivaldi Capital Management’s Novartis NVS Stock Holding History

Vivaldi Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,420	Closed	-$221K	–	241
2019 Q2	$221K	Buy	+2,420	New	+$205K	0.06%	209
2019 Q1	–	Sell	-3,563	Closed	-$274K	–	235
2018 Q4	$274K	Buy	+3,563	New	+$277K	0.12%	146

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

Vivaldi Capital Management's NVS Position: Q3 2019 in Review

Vivaldi Capital Management sold out of Novartis (NVS) in Q3 2019, closing a stake of 2,420 shares — an estimated $221K sold.

Vivaldi Capital Management first reported a position in NVS in Q4 2018 and held it in 2 quarters. The position peaked at $274K in Q4 2018. 1,090 funds tracked by Wall St. Rank hold NVS as of Q3 2019.

Vivaldi Capital Management reported no remaining Novartis position as of Q3 2019 after selling out during the quarter.
Vivaldi Capital Management sold 2,420 Novartis shares in Q3 2019, an estimated $221K.
Vivaldi Capital Management first reported a position in Novartis in Q4 2018 and held it in 2 quarters.
Vivaldi Capital Management's Novartis position peaked at $274K in Q4 2018.
1,090 funds tracked by Wall St. Rank held Novartis as of Q3 2019.

Based on Vivaldi Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.